BCM
BCYC

BlueCrest Capital Management’s Bicycle Therapeutics BCYC Stock Holding History

BlueCrest Capital Management’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-90,986
Closed -$1.04M – 405
2019
Q3 		$1.04M Buy
90,986
+20,986
+30% +$180K 0.07% 187
2019
Q2 		$704K Buy
+70,000
New +$843K 0.05% 177

Other funds holding BCYC

TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $122M AUM 26.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlueCrest Capital Management's BCYC Position: Q4 2019 in Review

BlueCrest Capital Management sold out of Bicycle Therapeutics (BCYC) in Q4 2019, closing a stake of 90,986 shares — an estimated $1.04M sold.

BlueCrest Capital Management first reported a position in BCYC in Q2 2019 and held it in 2 quarters. The position peaked at $1.04M in Q3 2019. 10 funds tracked by Wall St. Rank hold BCYC as of Q4 2019.

  • BlueCrest Capital Management reported no remaining Bicycle Therapeutics position as of Q4 2019 after selling out during the quarter.
  • BlueCrest Capital Management sold 90,986 Bicycle Therapeutics shares in Q4 2019, an estimated $1.04M.
  • BlueCrest Capital Management first reported a position in Bicycle Therapeutics in Q2 2019 and held it in 2 quarters.
  • BlueCrest Capital Management's Bicycle Therapeutics position peaked at $1.04M in Q3 2019.
  • 10 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q4 2019.

Based on BlueCrest Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.